Filtered By:
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 153 results found since Jan 2013.
An investigation of three injections techniques in reducing local injection pain with a human papillomavirus vaccine: A randomized trial.
CONCLUSIONS: Most injection site reactions in this study were mild. The three injection techniques used in this study were equivalent in their reactogenicity and pain profiles and could be recommended for use in this population.
PMID: 23306361 [PubMed - as supplied by publisher]
Source: Vaccine - January 8, 2013 Category: Allergy & Immunology Authors: Petousis-Harris H, Poole T, Stewart J, Turner N, Goodyear-Smith F, Coster G, Lennon D Tags: Vaccine Source Type: research
JAMA: 2009-08-19, Vol. 302, No. 7, Author in the Room™ Audio Interview
Interview with John Iskander, MD, author of Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine. Summary Points: 1. Since quadrivalent HPV vaccine was licensed in June 2006, more than 23 million doses have been administered nationally. 2. There were a total of 12,424 reports to the Vaccine Adverse Event Reporting System (VAERS) of adverse events following HPV vaccination through December 2008. The vast majority (94%) of adverse events reported to VAERS after receiving this vaccine have not been considered serious. The findings of this first published post-licensure safety review were...
Source: JAMA Author in the Room - October 23, 2009 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
JAMA: 2009-08-19, Vol. 302, No. 7, Author in the Room ™ Audio Interview
Interview with John Iskander, MD, author of Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine. Summary Points: 1. Since quadrivalent HPV vaccine was licensed in June 2006, more than 23 million doses have been administered nationally. 2. There were a total of 12,424 reports to the Vaccine Adverse Event Reporting System (VAERS) of adverse events following HPV vaccination through December 2008. The vast majority (94%) of adverse events reported to VAERS after receiving this vaccine have not been considered serious. The findings of this first published post-licensure safety review were...
Source: JAMA Author in the Room - October 23, 2009 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts